[Clinical evaluation of hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer]

Gan To Kagaku Ryoho. 1996 Sep;23(11):1443-6.
[Article in Japanese]

Abstract

Seventy-four cases of hepatic metastasis of colorectal cancer experienced in our hospital from January 1988 to February 1996 were examined for hepatic arterial infusion chemotherapy induced macrobiotic effect. A group (21 cases of hepatectomy and hepatic arterial infusion chemotherapy), B group (31 cases of hepatic arterial infusion chemotherapy only) and C group (22 cases of iv and po systemic chemotherapy) were comparatively examined for survival rate using Kaplan-Meier method. Single administration of adriamycin, epirubicin, cisplatin (CDDP) and 5-FU, along with CDDP-5-FU combined therapy and 5-FU 1,000 mg/5 hr intermittent continuous infusion therapy, were used. Mean survival period was 719 +/- 369, 426 +/- 417, 158 +/- 125 days for groups A, B and C, respectively. One-year survival rate by degrees of H factor was comparatively examined because of different H factor rates for these 3 groups. As a result, it proved to be 83 and 40% for groups A and B, respectively, in H1,2 cases and 32 and 11% for groups B and C, respectively, in H3 cases, with their respective significant differences (p < 0.05). Positive treatment, including hepatectomy, hepatic arterial infusion chemotherapy and the like, was suggested to contribute to patient macrobiosis.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology*
  • Doxorubicin / administration & dosage
  • Drug Administration Schedule
  • Epirubicin / administration & dosage
  • Fluorouracil / administration & dosage
  • Hepatic Artery
  • Humans
  • Infusion Pumps, Implantable*
  • Infusions, Intra-Arterial
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / mortality
  • Liver Neoplasms / secondary*
  • Middle Aged
  • Survival Rate

Substances

  • Epirubicin
  • Doxorubicin
  • Cisplatin
  • Fluorouracil